Orgenesis Inc
NASDAQ:ORGS

Watchlist Manager
Orgenesis Inc Logo
Orgenesis Inc
NASDAQ:ORGS
Watchlist
Price: 0.15 USD Market Closed
Market Cap: 960k USD
Section:
 

Relative Value

The Relative Value of one ORGS stock under the Base Case scenario is 1.53 USD. Compared to the current market price of 0.15 USD, Orgenesis Inc is Undervalued by 90%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ORGS Relative Value
Base Case
1.53 USD
Undervaluation 90%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1.1
P/S
P/S
Price to Sales
1.1
vs History
93
vs Industry
37
Median 3Y
5.3
Median 5Y
6.4
Industry
8.2
Forward
0
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
10
Median 3Y
-0.8
Median 5Y
-1.6
Industry
24.2
Forward
0.2
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-1.6
Median 5Y
-3.1
Industry
23
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
-3.1
Industry
25.5
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
55
Median 3Y
-0.3
Median 5Y
2.9
Industry
3.3
More Details
15.5
EV/S
EV/S
Enterprise Value to Sales
15.5
vs History
44
vs Industry
22
Median 3Y
19.8
Median 5Y
12.2
Industry
8.6
Forward
0.2
More Details
Negative
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
28
Median 3Y
-15.9
Median 5Y
-20.5
Industry
10.5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-1.7
Median 5Y
-4.2
Industry
6.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-1.6
Median 5Y
-4.2
Industry
6.6
Forward
0.8
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-4
Industry
8.8
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-2.1
Median 5Y
-3.2
Industry
6.8
More Details
0.9
EV/IC
EV/IC
Enterprise Value to IC
0.9
vs History
96
vs Industry
49
Median 3Y
1.6
Median 5Y
2.4
Industry
5.7
More Details

Multiples Across Competitors

ORGS Competitors Multiples
Orgenesis Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Orgenesis Inc
NASDAQ:ORGS
960k USD 1.1 -0 -0.6 -0.5
IL
Can Fite Biopharma Ltd
TASE:CANF
154.5T ILS 56 126 368 -3 854 397.8 -3 782 344.2 -3 773 924.8
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 079 720.5 -161 975.9 -196 690.4 -194 445.9
US
Abbvie Inc
NYSE:ABBV
390.1B USD 6.5 166.2 16.1 22.9
US
Amgen Inc
NASDAQ:AMGN
174.5B USD 4.9 24.9 18 18
US
Gilead Sciences Inc
NASDAQ:GILD
151.2B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.5B USD 9.9 31.4 23.1 24.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.2 -527.5 -574.4 -559.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.9B USD 5.6 17.5 16.6 18.9
AU
CSL Ltd
ASX:CSL
84.1B AUD 3.6 18.7 12.6 15.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD 15.2 1 119.2 150.8 182.9
P/S Multiple
Revenue Growth P/S to Growth
US
Orgenesis Inc
NASDAQ:ORGS
Average P/S: 8 200 746.1
1.1
N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
56 126 368
140%
400 902.6
FR
Pharnext SCA
OTC:PNEXF
34 079 720.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.5
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.9
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
10%
1
US
E
Epizyme Inc
F:EPE
2 067.2
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.6
6%
0.9
AU
CSL Ltd
ASX:CSL
3.6
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
15.2
46%
0.3
P/E Multiple
Earnings Growth PEG
US
Orgenesis Inc
NASDAQ:ORGS
Average P/E: 199.5
Negative Multiple: -0 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 854 397.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 975.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
166.2
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.4
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
10%
1.7
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 119.2
N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Orgenesis Inc
NASDAQ:ORGS
Average EV/EBITDA: 35.7
Negative Multiple: -0.6 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 782 344.2 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 690.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
AU
CSL Ltd
ASX:CSL
12.6
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
150.8
N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Orgenesis Inc
NASDAQ:ORGS
Average EV/EBIT: 42.1
Negative Multiple: -0.5 		N/A N/A
IL
C
Can Fite Biopharma Ltd
TASE:CANF
Negative Multiple: -3 773 924.8 N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 445.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
18
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.1 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.9
13%
1.5
AU
CSL Ltd
ASX:CSL
15.8
11%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
182.9
N/A N/A

See Also

Summary
ORGS intrinsic value, competitors valuation, and company profile.
DCF Valuation
ORGS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ORGS stock valuation using valuation multiples.
Wall Street Estimates
ORGS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ORGS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 309,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.